Kevin Eisenfrats is an entrepreneur whose passion lies at the intersection of biomedical engineering and reproductive medicine. He is the Co-Founder and CEO of Contraline, a medical device company based in Charlottesville, Virginia developing the first long lasting, non-hormonal, and reversible male contraceptive. The product, which has plans to hit the market in 2022, is comprised of a hydrogel that is implanted into the vas deferens via a quick, non-surgical procedure. The gel works by blocking sperm, and can be easily reversed when the patient desires their fertility be restored. Contraline has raised over $3 million to date from investors including Founders Fund, and has also participated in the Y Combinator Fellowship program.
Kevin graduated from the University of Virginia with a degree in Nanomedicine Engineering. Throughout his undergraduate career, he conducted research on immunotherapy and in vitro fertilization (IVF). Kevin continues to be actively involved in innovation and product development, being listed on 8 patents relating to novel medical devices, drug-delivery devices, and medical procedures. He has won multiple university and national competitions for the invention behind Contraline, and was recently recognized on the Forbes 30 Under 30 in Healthcare. Kevin and Contraline have been featured in Bloomberg Businessweek, MIT Technology Review, TechCrunch, MedGadget, and AskMen.